Study findings show a considerable CMD burden among ART-naive PWH, highlighting the need to integrate prevention interventions into HIV care protocols..

Researchers project a significant increase in heat-related CVD burden by 2050, emphasizing the need for climate adaptation policies.

At a nurse practitioner-owned and operated clinic, researchers performed continuous PDSA cycles of quality improvement to ...

A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.

Men with rheumatoid arthritis have increased odds for heart failure vs women, particularly those with coronary heart disease. Men with rheumatoid arthritis (RA) have higher odds of developing heart ...

Cancer doctors across the US are running short of essential generic chemotherapy drugs, sparking fear of widespread rationing.

Evolocumab therapy reduces the risk for major cardiovascular events in stable patients with prior percutaneous coronary intervention.

Only 49% of U.S. adults report being “cost secure,” meaning they can pay for the medical visits and treatments they need.

Eosinophilic AE-COPD is associated with a lower risk for major adverse cardiovascular events (MACE) compared with noneosinophilic AE-COPD.

The FDA has approved Tryngolza (olezarsen) to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (TG ≥500mg/dL).

Despite an increased risk for cardiovascular disease, women with resolved pregnancy-only hypertension lack adequate preventive health care.

Both non-HDL-C and apolipoprotein B levels independently predict ASCVD risk in patients not receiving statins.